The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Abstract
▪ Abstract The taxane class of antimicrotubule anticancer agents is perhaps the most important addition to the chemotherapeutic armamentarium against cancer over the past several decades. After only a brief period, the taxanes have not only demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head and neck, bladder, and esophagus, they have also demonstrated effectiveness in the initial therapy of earlier stages of cancer, a setting in which any new therapy is likely to make its greatest impact. The challenge now facing investigators is to develop strategies to maximize therapeutic benefits with the taxanes in the early stages, as well as the advanced stages, of many cancers. This review describes the preclinical features and clinical results of the two major taxanes, paclitaxel (Taxol®, Bristol-Myers Squibb) and docetaxel (Taxotere®, Rhone-Poulenc Rhorer).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Self-citationHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., & Wilson, L. (1996) · PubMed · Cited by 770
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Haldar, S., Chintapalli, J., & Croce, C. M. (1996) · PubMed · Cited by 651
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Cited by
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells
Yvon, A.-M. C., Wadsworth, P., & Jordan, M. A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.947 · Cited by 553
Recent Natural Products Based Drug Development: A Pharmaceutical Industry Perspective
Shu, Y.-Z. (1998) · Journal of Natural Products · doi:10.1021/np9800102 · Cited by 517
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Metadata
- Authors
- Rowinsky, M.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 1997-02
- Volume
- 48
- Issue
- 1
- Pages
- 353-374
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2154094988
- Cited by
- 721
- References
- 66
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS. https://app.cochat.ai/papers/10.1146/annurev.med.48.1.353
- The paper
- Rowinsky, M. (1997). THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.48.1.353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
